Genmab presents full data set for cancer drug

In April, the biotech firm released topline results from a phase II study of its treatment for large B-cell lymphoma, epcoritamab, and Genmab has now revealed the full picture.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
by marketwire, translated by daniel pedersen

On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading